BY SOPHARMA – EU
SUMMARY OF PRODUCT CHARACTERISTICS / Lydol sol. inj. 50 mg / ml /
1. NAME OF THE MEDICINAL PRODUCT
LYDOL 50 mg / ml solution for injection
LIDOL 50 mg / ml solution for injection
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 2 ml ampoule contains the active substance pethidine hydrochloride 100 mg.
3. PHARMACEUTICAL FORM / Lydol sol. inj. 50 mg / ml /
Solution for injection.
4. CLINICAL PARTICULARS
• Short-term response to moderate to severe pain, unresponsive to non-narcotic analgesics, including analgesia at birth;
• Preoperative medication;
• Analgesic under general anesthesia.
4.2. Dosage and method of administration
Lidol solution for injection is administered parenterally – subcutaneously, intramuscularly and intravenously. Intramuscular administration is recommended. For intravenous administration, a dilute solution at a concentration of 10 mg / ml (water for injections) is used. During infusion, the solution is diluted to a concentration of 1 mg / ml.
Severe renal colic, vascular spasms, extensive burns, acute myocardial infarction, cardiac asthma, severe trauma; for premedication; in the postoperative period; persistent neuralgia; inoperable plasmas.
DOSAGE AND ADMINISTRATION: Subcutaneously or intramuscularly 50 – 150 mg 1-2 times a day. It can be administered as an intravenous infusion at a dose of 15-35 mg / h. For premedication, it is administered in a dose of 50 – 100 mg intramuscularly, 1 hour before anesthesia. In children, it is administered intramuscularly at a dose of 1.1 – 1.76 mg / kg, but not more than 100 mg.